Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Respiratory Medicine Reviews
  4. Volume 21, Issue 2
  5. Article
Volume 21, Issue 2
  • ISSN: 1573-398X
  • E-ISSN: 1875-6387

Abstract

Cytomegalovirus (CMV) is a ubiquitous pathogen that causes asymptomatic infections in the healthy immunocompetent host but is responsible for severe disease in immunocompromised individuals, graft failure, and congenital disabilities. Recent research implicates CMV as a crucial determinant of immunosenescence (detrimental age-related alterations responsible for the decline of immune responsiveness) and, more generally, a marker of life expectancy. CMV serostatus has been linked to an increased risk of cardiovascular, respiratory, oncological, and non-specific mortality in a number of intriguing, if not entirely clear, studies. Through a deep and extensive selection of the most updated and relevant literature on the matter, we summarized the most significant evidence concerning the role of CMV in immunosenescence, as well as all-cause and disease-related mortality. As is widely known, viral infections play a substantial role in the development and progression of respiratory disorders and are a well-established trigger for their exacerbations. Consistent with current observations correlating CMV seropositivity to mortality by chronic pulmonary disease, in the second part of the review, we focused on CMV involvement in obstructive lung disorders. In light of available evidence, CMV serostatus could represent a useful biomarker for risk stratification or even an underestimated target in the pathogenesis of several diseases. Considering the somewhat conflicting results and the potential clinical implications for a direct role of CMV in multiple chronic diseases, including obstructive lung diseases, we hope the present work encourages further investigation on the topic.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/crmr/10.2174/011573398X307840240703045530
2024-07-24
2025-04-04

  • From This Site

    /content/journals/crmr/10.2174/011573398X307840240703045530
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. MocarskiE CourcelleC Cytomegaloviruses and their replication fields virol. KnipeD.M. HowleyP.M. Pass RF Cytomegalovirus In Fields Virology.4th edPhiladelphiaLippincott, Williams & Wilkins2001226292673
     [Google Scholar]
  2. LandolfoS. GariglioM. GribaudoG. LemboD. The human cytomegalovirus.Pharmacol. Ther.200398326929710.1016/S0163‑7258(03)00034‑212782241
     [Google Scholar]
  3. JothimaniD. VenugopalR. VijM. RelaM. Post liver transplant recurrent and de novo viral infections.Best Pract. Res. Clin. Gastroenterol.202046-4710168910.1016/j.bpg.2020.10168933158469
     [Google Scholar]
  4. DiovertiM.V. RazonableR.R. Cytomegalovirus.Microbiol. Spectr.2016444.4.2010.1128/microbiolspec.DMIH2‑0022‑201527726793
     [Google Scholar]
  5. DavisN.L. KingC.C. KourtisA.P. Cytomegalovirus infection in pregnancy.Birth Defects Res.2017109533634610.1002/bdra.2360128398680
     [Google Scholar]
  6. ZuhairM. SmitG.S.A. WallisG. JabbarF. SmithC. DevleesschauwerB. GriffithsP. Estimation of the worldwide seroprevalence of cytomegalovirus: A systematic review and meta-analysis.Rev. Med. Virol.2019293e203410.1002/rmv.203430706584
     [Google Scholar]
  7. McVoyM.A. AdlerS.P. Immunologic evidence for frequent age-related cytomegalovirus reactivation in seropositive immunocompetent individuals.J. Infect. Dis.1989160111010.1093/infdis/160.1.12543705
     [Google Scholar]
  8. WangG.C. KaoW.H.L. MurakamiP. XueQ.L. ChiouR.B. DetrickB. McDyerJ.F. SembaR.D. CasolaroV. WalstonJ.D. FriedL.P. Cytomegalovirus infection and the risk of mortality and frailty in older women: A prospective observational cohort study.Am. J. Epidemiol.2010171101144115210.1093/aje/kwq06220400465
     [Google Scholar]
  9. Söderberg-NauclérC. Does cytomegalovirus play a causative role in the development of various inflammatory diseases and cancer?J. Intern. Med.2006259321924610.1111/j.1365‑2796.2006.01618.x16476101
     [Google Scholar]
  10. PawelecG. DerhovanessianE. LarbiA. StrindhallJ. WikbyA. Cytomegalovirus and human immunosenescence.Rev. Med. Virol.2009191475610.1002/rmv.59819035529
     [Google Scholar]
  11. MüllerL. Di BenedettoS. PawelecG. The immune system and its dysregulation with aging.Subcell. Biochem.201991214310.1007/978‑981‑13‑3681‑2_230888648
     [Google Scholar]
  12. LarbiA. FranceschiC. MazzattiD. SolanaR. WikbyA. PawelecG. Aging of the immune system as a prognostic factor for human longevity.Physiology2008232647410.1152/physiol.00040.200718400689
     [Google Scholar]
  13. Müller-WerdanU. NudingS. OstM. Assessing inflammageing.Curr. Opin. Clin. Nutr. Metab. Care201720534634810.1097/MCO.000000000000039128768292
     [Google Scholar]
  14. PawelecG. KochS. FranceschiC. WikbyA. Human Immunosenescence.Ann. N. Y. Acad. Sci.200610671566510.1196/annals.1354.00916803971
     [Google Scholar]
  15. De MartinisM. FranceschiC. MontiD. GinaldiL. Inflamm-ageing and lifelong antigenic load as major determinants of ageing rate and longevity.FEBS Lett.2005579102035203910.1016/j.febslet.2005.02.05515811314
     [Google Scholar]
  16. SimanekA.M. DowdJ.B. ZajacovaA. AielloA.E. Unpacking the black box of total pathogen burden: Is number or type of pathogens most predictive of all-cause mortality in the United States?Epidemiol. Infect.2015143122624263410.1017/S095026881400321525518978
     [Google Scholar]
  17. FarberD.L. YudaninN.A. RestifoN.P. Human memory T cells: Generation, compartmentalization and homeostasis.Nat. Rev. Immunol.2014141243510.1038/nri356724336101
     [Google Scholar]
  18. TuW. RaoS. Mechanisms underlying T cell immunosenescence: Aging and cytomegalovirus infection.Front. Microbiol.20167211110.3389/fmicb.2016.0211128082969
     [Google Scholar]
  19. LooneyR.J. FalseyA. CampbellD. TorresA. KolassaJ. BrowerC. McCannR. MenegusM. McCormickK. FramptonM. HallW. AbrahamG.N. Role of cytomegalovirus in the T cell changes seen in elderly individuals.Clin. Immunol.199990221321910.1006/clim.1998.463810080833
     [Google Scholar]
  20. AielloA E FeinsteinL DowdJ B Income and markers of immunological cellular aging.Psychosom. Med.2016786657666
     [Google Scholar]
  21. HadrupSR StrindhallJ KøllgaardT Longitudinal studies of clonally expanded CD8 T cells reveal a repertoire shrinkage predicting mortality and an increased number of dysfunctional cytomegalovirus-specific T cells in the very elderly.J Immunol2006176426452653
     [Google Scholar]
  22. WeltevredeM. EilersR. de MelkerH.E. van BaarleD. Cytomegalovirus persistence and T-cell immunosenescence in people aged fifty and older: A systematic review.Exp. Gerontol.201677879510.1016/j.exger.2016.02.00526883338
     [Google Scholar]
  23. WertheimerAM BennettMS ParkB Aging and cytomegalovirus infection differentially and jointly affect distinct circulating T cell subsets in humans.J Immunol.2014192521432155
     [Google Scholar]
  24. GoronzyJ.J. FulbrightJ.W. CrowsonC.S. PolandG.A. O’FallonW.M. WeyandC.M. Value of immunological markers in predicting responsiveness to influenza vaccination in elderly individuals.J. Virol.20017524121821218710.1128/JVI.75.24.12182‑12187.200111711609
     [Google Scholar]
  25. KadambariS. KlenermanP. PollardA.J. Why the elderly appear to be more severely affected by COVID-19: The potential role of immunosenescence and CMV.Rev. Med. Virol.2020305e214410.1002/rmv.214432671966
     [Google Scholar]
  26. PatinE. HasanM. BergstedtJ. RouillyV. LibriV. UrrutiaA. AlanioC. ScepanovicP. HammerC. JönssonF. BeitzB. QuachH. LimY.W. HunkapillerJ. ZepedaM. GreenC. PiaseckaB. LeloupC. RoggeL. HuetzF. PeguilletI. LantzO. FontesM. Di SantoJ.P. ThomasS. FellayJ. DuffyD. Quintana-MurciL. AlbertM.L. Natural variation in the parameters of innate immune cells is preferentially driven by genetic factors.Nat. Immunol.201819330231410.1038/s41590‑018‑0049‑729476184
     [Google Scholar]
  27. ZhengQ. TaoR. GaoH. XuJ. ShangS. ZhaoN. HCMV-encoded UL128 enhances TNF-α and IL-6 expression and promotes PBMC proliferation through the MAPK/ERK pathway in vitro .Viral Immunol.20122529810510.1089/vim.2011.006422486303
     [Google Scholar]
  28. ZhuJ. QuyyumiA.A. NormanJ.E. CsakoG. EpsteinS.E. Cytomegalovirus in the pathogenesis of atherosclerosis.J. Am. Coll. Cardiol.19993461738174310.1016/S0735‑1097(99)00410‑610577564
     [Google Scholar]
  29. StreblowD.N. NelsonJ.A. OrloffS.L. Do pathogens accelerate atherosclerosis?J. Nutr.2001131102798S2804S10.1093/jn/131.10.2798S11584110
     [Google Scholar]
  30. SchmaltzH.N. FriedL.P. XueQ.L. WalstonJ. LengS.X. SembaR.D. Chronic cytomegalovirus infection and inflammation are associated with prevalent frailty in community-dwelling older women.J. Am. Geriatr. Soc.200553574775410.1111/j.1532‑5415.2005.53250.x15877548
     [Google Scholar]
  31. YooSG HanK Do LeeKH Epidemiological changes in cytomegalovirus end-organ diseases in a developed country: A nationwide, general-population-based study.J Microbiol Immunol Infect.2021S1684-11822100173
     [Google Scholar]
  32. BorenE. GershwinM.E. Inflamm-aging: Autoimmunity, and the immune-risk phenotype.Autoimmun. Rev.20043540140610.1016/j.autrev.2004.03.00415288008
     [Google Scholar]
  33. SansoniP. VescoviniR. FagnoniF.F. AkbarA. ArensR. ChiuY.L. Čičin-ŠainL. Dechanet-MervilleJ. DerhovanessianE. Ferrando-MartinezS. FranceschiC. FrascaD. FulöpT. FurmanD. Gkrania-KlotsasE. GoodrumF. Grubeck-LoebensteinB. HurmeM. KernF. LilleriD. López-BotetM. MaierA.B. MaranduT. MarchantA. MatheïC. MossP. MuntasellA. RemmerswaalE.B.M. RiddellN.E. RotheK. SauceD. ShinE.C. SimanekA.M. SmitheyM.J. Söderberg-NauclérC. SolanaR. ThomasP.G. van LierR. PawelecG. Nikolich-ZugichJ. New advances in CMV and immunosenescence.Exp. Gerontol.201455546210.1016/j.exger.2014.03.02024703889
     [Google Scholar]
  34. RobertsE.T. HaanM.N. DowdJ.B. AielloA.E. Cytomegalovirus antibody levels, inflammation, and mortality among elderly Latinos over 9 years of follow-up.Am. J. Epidemiol.2010172436337110.1093/aje/kwq17720660122
     [Google Scholar]
  35. MatheïC. AdriaensenW. VaesB. Van PottelberghG. WallemacqP. DegryseJ. No relation between CMV infection and mortality in the oldest old: Results from the Belfrail study.Age Ageing201544113013510.1093/ageing/afu09425026957
     [Google Scholar]
  36. MuhlesteinJ.B. HorneB.D. CarlquistJ.F. MadsenT.E. BairT.L. PearsonR.R. AndersonJ.L. Cytomegalovirus seropositivity and C-reactive protein have independent and combined predictive value for mortality in patients with angiographically demonstrated coronary artery disease.Circulation2000102161917192310.1161/01.CIR.102.16.191711034939
     [Google Scholar]
  37. BlankenbergS. RupprechtH.J. BickelC. Espinola-KleinC. RippinG. HafnerG. OssendorfM. SteinhagenK. MeyerJ. Cytomegalovirus infection with interleukin-6 response predicts cardiac mortality in patients with coronary artery disease.Circulation2001103242915292110.1161/01.CIR.103.24.291511413080
     [Google Scholar]
  38. YangF.J. ShuK.H. ChenH.Y. ChenI.Y. LayF.Y. ChuangY.F. WuC.S. TsaiW.C. PengY.S. HsuS.P. ChiangC.K. WangG. ChiuY.L. Anti-cytomegalovirus IgG antibody titer is positively associated with advanced T cell differentiation and coronary artery disease in end-stage renal disease.Immun. Ageing20181511510.1186/s12979‑018‑0120‑029988679
     [Google Scholar]
  39. SimanekA.M. DowdJ.B. PawelecG. MelzerD. DuttaA. AielloA.E. Seropositivity to cytomegalovirus, inflammation, all-cause and cardiovascular disease-related mortality in the United States.PLoS One201162e1610310.1371/journal.pone.001610321379581
     [Google Scholar]
  40. González-QuijadaS. del Álamo-Martínez de LagosM. Álvarez-LlabrésM. Pérez-GonzálezL. Cytomegalovirus antibody levels and mortality among hospitalised elderly patients.Ann. Med.202052849750510.1080/07853890.2020.181188832803995
     [Google Scholar]
  41. Gkrania-KlotsasE. LangenbergC. SharpS.J. LubenR. KhawK.T. WarehamN.J. Seropositivity and higher immunoglobulin G antibody levels against cytomegalovirus are associated with mortality in the population-based European prospective investigation of Cancer-Norfolk cohort.Clin. Infect. Dis.201356101421142710.1093/cid/cit08323442763
     [Google Scholar]
  42. WangH. PengG. BaiJ. HeB. HuangK. HuX. LiuD. Cytomegalovirus infection and relative risk of cardiovascular disease (ischemic heart disease, stroke, and cardiovascular death): A meta-analysis of prospective studies up to 2016.J. Am. Heart Assoc.201767e00502510.1161/JAHA.116.00502528684641
     [Google Scholar]
  43. WolfD. LeyK. Immunity and inflammation in atherosclerosis.Circ. Res.2019124231532710.1161/CIRCRESAHA.118.31359130653442
     [Google Scholar]
  44. EtinginO.R. SilversteinR.L. FriedmanH.M. HajjarD.P. Viral activation of the coagulation cascade: Molecular interactions at the surface of infected endothelial cells.Cell199061465766210.1016/0092‑8674(90)90477‑V2160855
     [Google Scholar]
  45. EpsteinS.E. ZhuJ. NajafiA.H. BurnettM.S. Insights into the role of infection in atherogenesis and in plaque rupture.Circulation2009119243133314110.1161/CIRCULATIONAHA.109.84945519546396
     [Google Scholar]
  46. HorneB.D. MuhlesteinJ.B. CarlquistJ.F. BairT.L. MadsenT.E. HartN.I. AndersonJ.L. Statin therapy interacts with cytomegalovirus seropositivity and high C-reactive protein in reducing mortality among patients with angiographically significant coronary disease.Circulation2003107225826310.1161/01.CIR.0000045668.71683.9212538425
     [Google Scholar]
  47. NeumannF.J. KastratiA. MiethkeT. Pogatsa-MurrayG. SeyfarthM. SchömigA. Previous cytomegalovirus infection and risk of coronary thrombotic events after stent placement.Circulation20001011111310.1161/01.CIR.101.1.1110618297
     [Google Scholar]
  48. SavvaG.M. PachnioA. KaulB. MorganK. HuppertF.A. BrayneC. MossP.A.H. Cytomegalovirus infection is associated with increased mortality in the older population.Aging Cell201312338138710.1111/acel.1205923442093
     [Google Scholar]
  49. ZiemannM. HeringlakeM. LenorP. JuhlD. HankeT. PetersenM. SchönJ. HeinzeH. GroesdonkH.V. PaarmannH. HennigH. Cytomegalovirus serostatus as predictor for adverse events after cardiac surgery: A prospective observational study.J. Cardiothorac. Vasc. Anesth.20173162042204810.1053/j.jvca.2016.10.02428073619
     [Google Scholar]
  50. SiscovickD.S. SchwartzS.M. CoreyL. GraystonJ.T. AshleyR. WangS.P. PsatyB.M. TracyR.P. KullerL.H. KronmalR.A. Chlamydia pneumoniae, herpes simplex virus type 1, and cytomegalovirus and incident myocardial infarction and coronary heart disease death in older adults : The Cardiovascular Health Study.Circulation2000102192335234010.1161/01.CIR.102.19.233511067785
     [Google Scholar]
  51. ModernaT.X.I. Study to evaluate the efficacy, safety, and immunogenicity of mRNA-1647 cytomegalovirus (CMV) vaccine in healthy participants 16 to 40 years of age. Clinical Trials.2021Available from: https://clinicaltrials.gov/ct2/show/NCT05085366 (Accessed April 23, 2022.)
  52. NicolettiF. ScaliaG. LunettaM. CondorelliF. Di MauroM. BarcelliniW. StracuzziS. PaganoM. MeroniP.L. Correlation between islet cell antibodies and anti-cytomegalovirus IgM and IgG antibodies in healthy first-degree relatives of type 1 (insulin-dependent) diabetic patients.Clin. Immunol. Immunopathol.199055113914710.1016/0090‑1229(90)90075‑22155076
     [Google Scholar]
  53. SmeltM.J. FaasM.M. De HaanB.J. Susceptibility of human pancreatic β cells for cytomegalovirus infection and the effects on cellular immunogenicity.Pancreas199055113914722158077
     [Google Scholar]
  54. MendyA. GasanaJ. VieiraE.R. DialloH. Prospective study of cytomegalovirus seropositivity and risk of mortality from diabetes.Acta Diabetol.201451572372910.1007/s00592‑014‑0573‑324633860
     [Google Scholar]
  55. CottoneM. PietrosiG. MartoranaG. CasàA. PecoraroG. OlivaL. OrlandoA. RosselliM. RizzoA. PagliaroL. Prevalence of cytomegalovirus infection in severe refractory ulcerative and Crohn’s colitis.Am. J. Gastroenterol.200196377377510.1111/j.1572‑0241.2001.03620.x11280549
     [Google Scholar]
  56. AhmedI. KassemW. SalamY. FurnariM. MehtaT. Outcome of cytomegalovirus colitis in inflammatory bowel disease with different regimes of ganciclovir.Middle East J. Dig. Dis.201810422022910.15171/mejdd.2018.11431049169
     [Google Scholar]
  57. HendlerS.A. BarberG.E. OkaforP.N. ChangM.S. LimsuiD. LimketkaiB.N. Cytomegalovirus infection is associated with worse outcomes in inflammatory bowel disease hospitalizations nationwide.Int. J. Colorectal Dis.202035589790310.1007/s00384‑020‑03536‑832124046
     [Google Scholar]
  58. TaherC. FriskG. FuentesS. ReligaP. CostaH. AssingerA. VetvikK.K. BukholmI.R.K. YaiwK.C. SmedbyK.E. BäcklundM. Söderberg-NauclerC. RahbarA. High prevalence of human cytomegalovirus in brain metastases of patients with primary breast and colorectal cancers.Transl. Oncol.20147673274010.1016/j.tranon.2014.09.00825500083
     [Google Scholar]
  59. CinatlJ.Jr VogelJ.U. KotchetkovR. Wilhelm DoerrH. Oncomodulatory signals by regulatory proteins encoded by human cytomegalovirus: A novel role for viral infection in tumor progression.FEMS Microbiol. Rev.2004281597710.1016/j.femsre.2003.07.00514975530
     [Google Scholar]
  60. OkedeleO.O. NelsonH.H. OyenugaM.L. ThyagarajanB. PrizmentA. Cytomegalovirus and cancer-related mortality in the national health and nutritional examination survey.Cancer Causes Control202031654154710.1007/s10552‑020‑01296‑y32222844
     [Google Scholar]
  61. NennaR. ZhaiJ. PackardS.E. SpangenbergA. SherrillD.L. MartinezF.D. HalonenM. GuerraS. High cytomegalovirus serology and subsequent COPD-related mortality: A longitudinal study.ERJ Open Res.20206200062-202010.1183/23120541.00062‑202032363208
     [Google Scholar]
  62. SelveyL.A. LimW.H. BoanP. SwaminathanR. SlimingsC. HarrisonA.E. ChakeraA. Cytomegalovirus viraemia and mortality in renal transplant recipients in the era of antiviral prophylaxis. Lessons from the western Australian experience.BMC Infect. Dis.201717150110.1186/s12879‑017‑2599‑y28716027
     [Google Scholar]
  63. KottonC.N. KumarD. CaliendoA.M. HuprikarS. ChouS. Danziger-IsakovL. HumarA. The third international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation.Transplantation2018102690093110.1097/TP.000000000000219129596116
     [Google Scholar]
  64. EinseleH. LjungmanP. BoeckhM. How I treat CMV reactivation after allogeneic hematopoietic stem cell transplantation.Blood2020135191619162910.1182/blood.201900095632202631
     [Google Scholar]
  65. GreenM.L. LeisenringW. XieH. MastT.C. CuiY. SandmaierB.M. SorrorM.L. GoyalS. ÖzkökS. YiJ. SahooF. KimballL.E. JeromeK.R. MarksM.A. BoeckhM. Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: A retrospective cohort study.Lancet Haematol.201633e119e12710.1016/S2352‑3026(15)00289‑626947200
     [Google Scholar]
  66. LjungmanP. SchmittM. MartyF.M. MaertensJ. ChemalyR.F. KartsonisN.A. ButtertonJ.R. WanH. TealV.L. SarrattK. MurataY. LeavittR.Y. BadshahC. A mortality analysis of letermovir prophylaxis for Cytomegalovirus (CMV) in CMV-seropositive recipients of allogeneic hematopoietic cell transplantation.Clin. Infect. Dis.20207081525153310.1093/cid/ciz49031179485
     [Google Scholar]
  67. MartyF.M. WinstonD.J. ChemalyR.F. MullaneK.M. ShoreT.B. PapanicolaouG.A. ChittickG. BrundageT.M. WilsonC. MorrisonM.E. FosterS.A. NicholsW.G. BoeckhM.J. A randomized, double-blind, placebo-controlled phase 3 trial of oral brincidofovir for cytomegalovirus prophylaxis in allogeneic hematopoietic cell transplantation.Biol. Blood Marrow Transplant.201925236938110.1016/j.bbmt.2018.09.03830292744
     [Google Scholar]
  68. PlotkinS. FriedmanH.M. FleisherG.R. DafoeD.C. GrossmanR.A. Lynn SmileyM. StarrS.E. WlodaverC. FriedmanA.D. BarkerC. Towne-vaccine-induced prevention of cytomegalovirus disease after renal transplants.Lancet1984323837652853010.1016/S0140‑6736(84)90930‑96142252
     [Google Scholar]
  69. GriffithsP.D. StantonA. McCarrellE. SmithC. OsmanM. HarberM. DavenportA. JonesG. WheelerD.C. O’BeirneJ. ThorburnD. PatchD. AtkinsonC.E. PichonS. SwenyP. LanzmanM. WoodfordE. RothwellE. OldN. KinyanjuiR. HaqueT. AtabaniS. LuckS. PrideauxS. MilneR.S.B. EmeryV.C. BurroughsA.K. Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: A phase 2 randomised placebo-controlled trial.Lancet201137797731256126310.1016/S0140‑6736(11)60136‑021481708
     [Google Scholar]
  70. Kharfan-DabajaM.A. BoeckhM. WilckM.B. LangstonA.A. ChuA.H. WlochM.K. GuterwillD.F. SmithL.R. RollandA.P. KenneyR.T. A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: A randomised, double-blind, placebo- controlled, phase 2 trial.Lancet Infect. Dis.201212429029910.1016/S1473‑3099(11)70344‑922237175
     [Google Scholar]
  71. GriffithsP. The direct and indirect consequences of cytomegalovirus infection and potential benefits of vaccination.Antiviral Res.202017610473210.1016/j.antiviral.2020.10473232081353
     [Google Scholar]
  72. ChenS. PawelecG. TrompetS. GoldeckD. MortensenL.H. SlagboomP.E. ChristensenK. GusseklooJ. KearneyP. BuckleyB.M. FordI. JukemaJ.W. WestendorpR.G.J. MaierA.B. Associations of cytomegalovirus infection with all-cause and cardiovascular mortality in multiple observational cohort studies of older adults.J. Infect. Dis.2021223223824610.1093/infdis/jiaa48032909605
     [Google Scholar]
  73. AdlerS.P. BestA.M. MarshallB. VetrovecG.W. Infection with cytomegalovirus is not associated with premature mortality.Infect. Dis. Rep.201132e1710.4081/idr.2011.325724470914
     [Google Scholar]
  74. HaesekerM.B. PijpersE. Dukers-MuijrersN.H.T.M. NelemansP. HoebeC.J.P.A. BruggemanC.A. VerbonA. GoossensV.J. Association of cytomegalovirus and other pathogens with frailty and diabetes mellitus, but not with cardiovascular disease and mortality in psycho-geriatric patients; a prospective cohort study.Immun. Ageing20131013010.1186/1742‑4933‑10‑3023880245
     [Google Scholar]
  75. Joanna Briggs InstituteJoanna Briggs Institute critical appraisal tools.Available from: https://jbi.global/critical-appraisal-tools (Accessed July 19, 2022).
  76. ChoiS. SohnK.H. JungJ.W. KangM.G. YangM.S. KimS. ChoiJ.H. ChoS.H. KangH.R. YiH. Lung virome: New potential biomarkers for asthma severity and exacerbation.J. Allergy Clin. Immunol.2021148410071015.e910.1016/j.jaci.2021.03.01733757721
     [Google Scholar]
  77. LindenD. Guo-ParkeH. CoyleP.V. FairleyD. McAuleyD.F. TaggartC.C. KidneyJ. Respiratory viral infection: A potential missing link in the pathogenesis of COPD.Eur. Respir. Rev.20192815118006310.1183/16000617.0063‑201830872396
     [Google Scholar]
  78. KowalskiM.L. WardzynskaA. StudzinskaM. PawelczykM. LesnikowskiZ.J. ParadowskaE. Cytomegalovirus DNA is highly prevalent in the blood of patients with asthma and is associated with age and asthma traits.Allergy201772122035203810.1111/all.1323328643373
     [Google Scholar]
  79. SunH. LiS. YanY. ChenZ. WangY. HaoC. JiW. Associations between patient clinical characteristics and the presence of cytomegalovirus DNA in the bronchoalveolar lavage fluid of children with recurrent wheezing.BMC Infect. Dis.201818145810.1186/s12879‑018‑3345‑930200894
     [Google Scholar]
  80. SawantA. SpoletiniG. WhitakerP. EtheringtonC. CliftonI. PeckhamD. Cytomegalovirus-associated pulmonary exacerbation in patients with cystic fibrosis.ERJ Open Res.20184100111-201710.1183/23120541.00111‑201729333432
     [Google Scholar]
  81. ParkinsM.D. RamosK.J. GossC.H. SomayajiR. Cytomegalovirus: An unrecognised potential contributor to cystic fibrosis disease progression?Eur. Respir. J.2019534180172710.1183/13993003.01727‑201830956206
     [Google Scholar]
  82. YawnB.P. MintzM.L. DohertyD.E. Gold in practice: Chronic obstructive pulmonary disease treatment and management in the primary care setting.Int. J. Chron. Obstruct. Pulmon. Dis.20211628929910.2147/COPD.S22266433603355
     [Google Scholar]
  83. MatéI. Martínez de TodaI. ArranzL. Álvarez-SalaJ.L. De la FuenteM. Accelerated immunosenescence, oxidation and inflammation lead to a higher biological age in COPD patients.Exp. Gerontol.202115411155110.1016/j.exger.2021.11155134530106
     [Google Scholar]
  84. ChoudhuryG. MacNeeW. Role of inflammation and oxidative stress in the pathology of ageing in COPD: Potential therapeutic interventions.COPD202115411155127624918
     [Google Scholar]
  85. BurkesR. OsterburgA. HwalekT. LachL. PanosR.J. BorchersM.T. Cytomegalovirus seropositivity is associated with airflow limitation in a cohort of veterans with a high prevalence of smoking.Chronic Obstr. Pulm. Dis.20218444144910.15326/jcopdf.2021.022134329551
     [Google Scholar]
  86. TanD.B.A. AmranF.S. TeoT.H. PriceP. MoodleyY.P. Levels of CMV-reactive antibodies correlate with the induction of CD28null T cells and systemic inflammation in chronic obstructive pulmonary disease (COPD).Cell. Mol. Immunol.201613455155310.1038/cmi.2015.427402584
     [Google Scholar]
  87. LambersC. HackerS. PoschM. HoetzeneckerK. PollreiszA. LichtenauerM. KlepetkoW. Jan AnkersmitH. T cell senescence and contraction of T cell repertoire diversity in patients with chronic obstructive pulmonary disease.Clin. Exp. Immunol.2009155346647510.1111/j.1365‑2249.2008.03835.x19220836
     [Google Scholar]
  88. HodgeG. NairnJ. HolmesM. ReynoldsP.N. HodgeS. Increased intracellular T helper 1 proinflammatory cytokine production in peripheral blood, bronchoalveolar lavage and intraepithelial T cells of COPD subjects.Clin. Exp. Immunol.20071501222910.1111/j.1365‑2249.2007.03451.x17614970
     [Google Scholar]
  89. BarnesP.J. Senescence in COPD and its comorbidities.Annu. Rev. Physiol.201779151753910.1146/annurev‑physiol‑022516‑03431427959617
     [Google Scholar]
  90. Martínez de TodaI. VidaC. Díaz-Del CerroE. De la FuenteM. The immunity clock.J. Gerontol. A Biol. Sci. Med. Sci.202176111939194510.1093/gerona/glab13633979432
     [Google Scholar]
  91. Antonio Moro-GarciaM. Alonso-AriasR. López-LarreaC. Molecular mechanisms involved in the aging of the T-cell immune response.Curr. Genomics201213858960210.2174/13892021280375974923730199
     [Google Scholar]
/content/journals/crmr/10.2174/011573398X307840240703045530
Loading
Cytomegalovirus and Mortality Risk: Is there also a Role in Obstructive Lung Diseases?
Current Respiratory Medicine Reviews 21, 109 (2025); https://doi.org/10.2174/011573398X307840240703045530
/content/journals/crmr/10.2174/011573398X307840240703045530
/content/journals/crmr/10.2174/011573398X307840240703045530
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): COPD; cytomegalovirus; immunosenescence; mortality; obstructive lung diseases; serology

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test